Analysts Expect Stemline Therapeutics Inc (NASDAQ:STML) to Post -$0.49 Earnings Per Share

Equities research analysts predict that Stemline Therapeutics Inc (NASDAQ:STML) will announce earnings per share (EPS) of ($0.49) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.54) to ($0.38). Stemline Therapeutics posted earnings of ($0.66) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 25.8%. The firm is expected to report its next earnings report on Thursday, August 8th.

On average, analysts expect that Stemline Therapeutics will report full year earnings of ($2.14) per share for the current year, with EPS estimates ranging from ($3.01) to ($1.55). For the next year, analysts anticipate that the company will report earnings of $0.29 per share, with EPS estimates ranging from ($1.25) to $2.12. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Stemline Therapeutics.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million during the quarter, compared to the consensus estimate of $2.61 million.

A number of brokerages have recently weighed in on STML. BidaskClub upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, June 22nd. Roth Capital reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Thursday, May 23rd. HC Wainwright set a $35.00 price objective on Stemline Therapeutics and gave the stock a “buy” rating in a research report on Thursday, June 20th. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. Finally, ValuEngine lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 15th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Stemline Therapeutics has an average rating of “Buy” and a consensus price target of $25.20.

In related news, COO Kenneth Hoberman sold 25,817 shares of Stemline Therapeutics stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $14.27, for a total value of $368,408.59. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 13.10% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Metropolitan Life Insurance Co NY boosted its holdings in Stemline Therapeutics by 56.7% during the first quarter. Metropolitan Life Insurance Co NY now owns 13,358 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 4,835 shares during the last quarter. MetLife Investment Advisors LLC boosted its holdings in Stemline Therapeutics by 54.6% during the first quarter. MetLife Investment Advisors LLC now owns 18,471 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 6,524 shares during the last quarter. Knott David M boosted its holdings in Stemline Therapeutics by 1.3% during the first quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock worth $2,028,000 after buying an additional 2,000 shares during the last quarter. Rubric Capital Management LP bought a new position in Stemline Therapeutics during the first quarter worth about $38,614,000. Finally, Fosun International Ltd boosted its holdings in Stemline Therapeutics by 362.0% during the first quarter. Fosun International Ltd now owns 267,936 shares of the biopharmaceutical company’s stock worth $3,293,000 after buying an additional 209,936 shares during the last quarter. Hedge funds and other institutional investors own 77.66% of the company’s stock.

Shares of NASDAQ:STML traded up $0.07 during midday trading on Friday, reaching $15.08. The company’s stock had a trading volume of 225 shares, compared to its average volume of 403,763. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $17.85. The company has a market capitalization of $658.85 million, a P/E ratio of -5.07 and a beta of 1.25. The company has a quick ratio of 5.03, a current ratio of 5.07 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $14.58.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: What is the 52-week high/low?

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.